Bigworld, I don't think we are out of the game. Our management has shown poor business sense for sure, but Aldevron would not be persuing synDNA if it weren't the real thing. FDA approvals for vaccines may be a few years off for use here in the USA, but Aldevron has many customers that use DNA. Some of these customers may have needs in the field of agriculture or may involve other countries that are able to get their own version of our FDA on a fast track. Even if CYGX can only produce 10 grams of synDNA per day at an introductory rate of $25K to $50K per gram, it would go a long way toward funding their own expansion.
Expansion doesn't have to be in the form of a new plant but in the addition of new machines, which if memory serves, can be built in 4 to 6 weeks. The longer range plans are what we want to grow the company in a big way.
I do not think that debt financing can be obtained here unless they get involved with a venture capital company or big pharma, which would act in the same way as a venture capital backer, and it would all be at our expense. Either party would create a debt instrument or superior stock position to ours, which would have to be serviced or the lender would be able to improve their ownship and control position at our expense. An angel or REIT might be found to build their new facility at a favorable lease rate and perhaps give an option for the company to buy down the road. I hate to say it, but it is our best interests (IMHO) to have them bumble along with their PPOs (I have not been invited to participate by the way and wouldn't until I see more).
If this science works and sells, however, it is time to bring in real business types. Venture cap and big pharma (joint venture) would do that but they wouldn't be thinking about us. Been around this arena for a long time. By the way, I appreciate your very fine and sincere posts, take care.
